Prevalence of Hypoxia and Correlation with Glycolytic Metabolism and Angiogenic Biomarkers in Metastatic Colorectal Carcinoma

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2020 Oct 30

PMID 33125527

Citations 3

Authors

S T Lee

V Muralidharan

N Tebbutt

P Wong

C Fang

Z Liu

H Gan

J Sachinidis

K Pathmaraj

C Christophi

A M Scott

Affiliations

Soon will be listed here.

Abstract

Purpose: Hypoxia is associated with aggressive tumour behaviour and can influence response to systemic therapy and radiotherapy. The prevalence of hypoxia in metastatic colorectal cancer is poorly understood, and the relationship of hypoxia to patient outcomes has not been clearly established. The aims of the study were to evaluate hypoxia in metastatic colorectal cancer with [F]Fluoromisonidazole ([F]FMISO PET) and correlate these findings with glycolytic metabolism ([F]FDG PET) and angiogenic blood biomarkers and patient outcomes.

Methods: Patients with metastatic colorectal cancer received routine staging investigations and both [F] FMISO PET and [F] FDG PET scans. Correlative blood specimens were also obtained at the time of the [F] FMISO PET scan. Patient follow-up was performed to establish progression-free survival.

Results: A total of 40 patients were recruited into the trial. [F]FMISO and [F]FDG PET scans showed a significant correlation of SUV (p = 0.003). A significant correlation of progression-free survival and [F] FMISO TNR (p = 0.02) and overall survival with [F]FMISO TNR (p = 0.003) and [F]FDG TGV (p = 0.02) was observed. Serum levels of osteopontin, but not VEGF, correlated with [F] FMISO and [F]FDG PET scan parameters.

Conclusion: [F]FMISO PET uptake in metastatic colorectal cancer significantly correlates with glycolytic metabolism and is predictive of progression-free and overall survival. These findings have implications for the assessment and treatment of metastatic colorectal cancer patients with novel therapies which affect tumour angiogenesis and hypoxia.

Citing Articles

The Effect of the Concurrent Use of Angiotensin-Converting Enzyme Inhibitors or Receptor Blockers on Toxicity and Outcomes in Patients Treated with Radiotherapy: A Systematic Review and Meta-Analysis.

Liao W, Shokr H, Faivre-Finn C, Dempsey C, Williams K, Chen L Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861167 PMC: 11769270. DOI: 10.3390/ph18010105.

Comprehensive Imaging Characterization of Colorectal Liver Metastases.

Maclean D, Tsakok M, Gleeson F, Breen D, Goldin R, Primrose J Front Oncol. 2021; 11:730854.

PMID: 34950575 PMC: 8688250. DOI: 10.3389/fonc.2021.730854.

Molecular Imaging of Angiogenesis in Oncology: Current Preclinical and Clinical Status.

Florea A, Mottaghy F, Bauwens M Int J Mol Sci. 2021; 22(11).

PMID: 34073992 PMC: 8197399. DOI: 10.3390/ijms22115544.

The role of the renin-angiotensin system inhibitors in malignancy: a review.

Yang J, Yang X, Gao L, Zhang J, Yi C, Huang Y Am J Cancer Res. 2021; 11(3):884-897.

PMID: 33791161 PMC: 7994166.

References

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

Nanji S, Cleary S, Ryan P, Guindi M, Selvarajah S, Al-Ali H . Up-front hepatic resection for metastatic colorectal cancer results in favorable long-term survival. Ann Surg Oncol. 2012; 20(1):295-304. DOI: 10.1245/s10434-012-2424-1. View

Pessaux P, Lermite E, Brehant O, Tuech J, Lorimier G, Arnaud J . Repeat hepatectomy for recurrent colorectal liver metastases. J Surg Oncol. 2005; 93(1):1-7. DOI: 10.1002/jso.20384. View

Poston G, Adam R, Alberts S, Curley S, Figueras J, Haller D . OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol. 2005; 23(28):7125-34. DOI: 10.1200/JCO.2005.08.722. View

Laurens S, Oyen W . Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer. PET Clin. 2015; 10(3):345-60. DOI: 10.1016/j.cpet.2015.03.007. View

Scott A, Gunawardana D, Kelley B, Stuckey J, Byrne A, Ramshaw J . PET changes management and improves prognostic stratification in patients with recurrent colorectal cancer: results of a multicenter prospective study. J Nucl Med. 2008; 49(9):1451-7. DOI: 10.2967/jnumed.108.051615. View

McIntyre A, Harris A . Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality. EMBO Mol Med. 2015; 7(4):368-79. PMC: 4403040. DOI: 10.15252/emmm.201404271. View

Schulze A, Harris A . How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature. 2012; 491(7424):364-73. DOI: 10.1038/nature11706. View

Bensaad K, Favaro E, Lewis C, Peck B, Lord S, Collins J . Fatty acid uptake and lipid storage induced by HIF-1α contribute to cell growth and survival after hypoxia-reoxygenation. Cell Rep. 2014; 9(1):349-365. DOI: 10.1016/j.celrep.2014.08.056. View

10.

Ros S, Schulze A . Balancing glycolytic flux: the role of 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatases in cancer metabolism. Cancer Metab. 2013; 1(1):8. PMC: 4178209. DOI: 10.1186/2049-3002-1-8. View

11.

Cantelmo A, Pircher A, Kalucka J, Carmeliet P . Vessel pruning or healing: endothelial metabolism as a novel target?. Expert Opin Ther Targets. 2017; 21(3):239-247. PMC: 5526136. DOI: 10.1080/14728222.2017.1282465. View

12.

Seeber A, Gunsilius E, Gastl G, Pircher A . Anti-Angiogenics: Their Value in Colorectal Cancer Therapy. Oncol Res Treat. 2018; 41(4):188-193. DOI: 10.1159/000488301. View

13.

Ferrara N, Gerber H, LeCouter J . The biology of VEGF and its receptors. Nat Med. 2003; 9(6):669-76. DOI: 10.1038/nm0603-669. View

14.

Sturrock M, Miller I, Kang G, Arbaie N, OFarrell A, Barat A . Anti-angiogenic drug scheduling optimisation with application to colorectal cancer. Sci Rep. 2018; 8(1):11182. PMC: 6060139. DOI: 10.1038/s41598-018-29318-5. View

15.

Lee S, Scott A . Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole. Semin Nucl Med. 2007; 37(6):451-61. DOI: 10.1053/j.semnuclmed.2007.07.001. View

16.

Gagel B, Reinartz P, Dimartino E, Zimny M, Pinkawa M, Maneschi P . pO(2) Polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F]-2-fluoro-2'-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia. Strahlenther Onkol. 2004; 180(10):616-22. DOI: 10.1007/s00066-004-1229-y. View

17.

Lawrentschuk N, Poon A, Foo S, Putra L, Murone C, Davis I . Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU Int. 2005; 96(4):540-6. DOI: 10.1111/j.1464-410X.2005.05681.x. View

18.

Fleming I, Manavaki R, Blower P, West C, Williams K, Harris A . Imaging tumour hypoxia with positron emission tomography. Br J Cancer. 2014; 112(2):238-50. PMC: 4453462. DOI: 10.1038/bjc.2014.610. View

19.

Zhao M, Liang F, Zhang B, Yan W, Zhang J . The impact of osteopontin on prognosis and clinicopathology of colorectal cancer patients: a systematic meta-analysis. Sci Rep. 2015; 5:12713. PMC: 4522607. DOI: 10.1038/srep12713. View

20.

Nordsmark M, Bentzen S, Overgaard J . Measurement of human tumour oxygenation status by a polarographic needle electrode. An analysis of inter- and intratumour heterogeneity. Acta Oncol. 1994; 33(4):383-9. DOI: 10.3109/02841869409098433. View